Symptoms and left ventricular size and function in patients with chronic aortic regurgitation**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.  by Gaasch, William H. & Schick, Edgar C.
EDITORIAL COMMENT
Symptoms and Left
Ventricular Size and
Function in Patients With
Chronic Aortic Regurgitation*
William H. Gaasch, MD, FACC,
Edgar C. Schick, MD, FACC
Burlington, Massachusetts
Patients with chronic aortic regurgitation (AR) are generally
subject to low morbidity during a long asymptomatic period;
many patients, even those with a severe regurgitant lesion,
remain asymptomatic for decades. Others, while lacking
clear evidence of worsening regurgitation, show evidence of
progressive left ventricular (LV) overload and eventually
develop symptoms or LV dysfunction. Conventional wis-
dom holds that the development of cardiac symptoms
and/or the development of LV dysfunction can be taken as
an indication for surgical correction of the regurgitant lesion
(1). In this issue of the Journal, Tarasoutchi et al. (2) report
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their experience with a “symptom-based strategy” in 75
patients with chronic AR. Testing the hypothesis that
outcomes achieved with this strategy might better suit the
socioeconomic feature of their patient population, they did
not rely on changes in LV size or function, but rather waited
for the development of symptoms before proceeding with
surgery. Their rationale for adopting this approach was to
“avoid early exposure to the complications of valve
prosthesis.”
On first glance the conclusion of Tarasoutchi et al. (2)
appear to be at odds with some of the recommendations
published in the American College of Cardiology/American
Heart Association (ACC/AHA) guidelines for the manage-
ment of patients with valvular heart disease (1). Their study
was prospective with clinical, echocardiographic, and exer-
cise evaluations every 6 to 12 months. At the time of the
baseline studies, virtually all patients had LV enlargement
and a normal LV ejection fraction (EF). After 10 years, 38
patients remained asymptomatic with relatively minor
changes in LV size and function. The other 37 patients
developed symptoms (after an average of 4.6 1.0 year) and
surgery was then recommended. Aortic valve replacement
(AVR) was performed in 34 patients (average 5.9  2.5
years). Three unoperated patients died and there were four
late deaths related to prosthetic valve endocarditis, throm-
bosis, or dysfunction. There were no deaths related to heart
failure. Sixty-eight patients (90%) were alive and well at the
end of the 10-year study period.
It is important to emphasize that virtually all of the
patients in this study had a normal LV EF; only two
asymptomatic patients had an EF 50%. Certainly “favor-
able” outcomes in only two patients cannot be used to
support the use of a symptom-based strategy in all patients
with a depressed EF. It does appear, however, that substan-
tial LV enlargement did not portend a poor outcome in
these relatively young patients with rheumatic valvular
disease. With these possible exceptions, the “symptom-
based strategy” is consonant with the approach presented in
the ACC/AHA guidelines.
LV response. Chronic AR burdens the heart with a vol-
ume load that leads to a series of compensatory myocardial
and circulatory adjustments (3,4). The major adjustment is
enlargement of the ventricle. An increase in end-diastolic
volume is crucial because it provides the only sustainable
mechanism for generation of a stroke volume large enough
to allow a normal systemic blood flow despite a significant
regurgitant fraction. Thus, a large end-diastolic volume is a
necessary and an expected compensatory adaptation to the
regurgitant lesion and in this regard it is similar to that seen
in chronic mitral regurgitation (5). Mitral regurgitation,
however, produces a relatively pure LV volume overload,
while AR produces a combined LV volume and pressure
overload with a combination of eccentric and concentric
hypertrophy. During the compensated stage of chronic AR,
myocardial function may not be entirely normal, but the
ventricular EF remains in the normal range and most
patients remain asymptomatic for years or even decades.
LV chamber size. Recognizing that ventricular enlarge-
ment is an obligatory adjustment to the volume load
imposed by chronic AR, the mere presence of a large
end-diastolic dimension (EDD) can be considered only a
marker of hemodynamically significant AR. The question
then arises: at what point can measurements of EDD be
useful in managing patients with chronic AR? Certainly
modest LV enlargement with normal systolic function
carries a benign prognosis (6). The implications of extreme
or progressive chamber enlargement are less certain.
Asymptomatic patients with a normal EF but extreme
LV enlargement (i.e., EDD 75 mm) is considered a class
IIa indication for AVR. This recommendation is based
largely on a report of sudden death in two of three patients
with an EDD 80 mm (7). However, other reports suggest
that extreme LV enlargement may not be so ominous. For
example, Klodas et al. (8) analyzed postoperative results in
31 patients with an EDD80 mm. In this study, the EDD
was not predictive of survival, EF, or functional class (FC);
severe chamber enlargement in the absence of systolic
dysfunction did not preclude a satisfactory clinical outcome.
In the Tarasoutchi et al. (2) study, 27 of the 75 patients had
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an EDD 75 mm; 20 patients eventually developed symp-
toms while 7 patients remained asymptomatic. Despite this
degree of enlargement, LV function remained normal and
clinical outcome was favorable. These studies do not
strongly support the use of extreme LV enlargement as an
indication for AVR—unless cardiac symptoms and/or sys-
tolic dysfunction are present.
Is a progressive increase in LV chamber size a more
cogent indication for AVR? Tarasoutchi et al. (2) found no
change in the mean value for EDD between baseline and
the final 10-year study in the 38 patients who remained
asymptomatic (although EDD increased from 75mm to
75mm in several patients), nor did a change in EDD
correspond to the development of symptoms. These obser-
vations are similar to those of Bonow et al. (6), who found
that EDD did not change significantly between their early
and late studies; over an average of 49 months only 15% of
their patients exhibited an increase in EDD that was more
than 5 mm. Therefore, it appears that the vast majority of
patients with chronic severe AR exhibit little or no change
in EDD for periods ranging from 4 to 10 years and that the
development of LV dysfunction cannot be correlated closely
with progressive LV enlargement. Certainly patients exhib-
iting progressive LV enlargement should be followed
closely, but a gradual increase in EDD in an asymptomatic
patient with a normal EF is not necessarily an indication for
AVR—unless accompanied by cardiac symptoms and/or
LV systolic dysfunction.
LV systolic function. Clinical investigators have repeat-
edly confirmed the importance of LV systolic function as a
determinant of clinical outcome in patients with chronic
AR. Ejection fraction and the echocardiographic fractional
shortening are the most widely used and accepted indices of
systolic function. The end-systolic diameter (ESD) is also
often used, but it should be recognized that end-systolic size
is a function of diastolic chamber size and contractile
function; end-systolic volume may increase as a consequence
of a larger end-diastolic volume and/or a lower EF. An
ESD55 mm is essentially a surrogate for impaired systolic
function because it will be associated with a reduced
shortening fraction when the EDD is 80 mm. Since the
ESD depends on LV chamber size and systolic function, as
well as body size, either the EF or shortening fraction
should be superior to the ESD because these parameters are
dimensionless and independent of body size (vide infra).
Tarasoutchi et al. (2) report that the majority of their
patients had normal systolic function at baseline; the EF was
50% in 72 of the 75 patients. Over the 10-year follow-up
period, they found a tendency for EF and shortening
fraction to decline in asymptomatic patients; approximately
one-third of patients exhibited a progressive increase in
ESD, but only one patient in each group showed an
abnormal EF that was not present in the baseline study.
Likewise, Bonow et al. (6) found a significant decline in EF
(5%) and an increase in ESD in patients who remained
stable as well as in those that required AVR. Thus, systolic
function, measured by any of the standard techniques, tends
to decline in many, but not all, patients with severe AR.
These changes are harbingers of the development of symp-
toms, and can be used to identify patients who may soon
require AVR. However, it does not appear that a progressive
decline in systolic function should be used as a strong
indication for AVR in an asymptomatic patient—unless the
EF falls below 50%.
Symptoms. Most published papers and texts indicate that
symptoms are an unequivocal indication for AVR, but a
careful definition of symptoms is rarely provided. The
interpretation of a patient’s description of symptoms, how-
ever, is often difficult and clinicians are forced to consider
the contributions of other medical conditions, such as
chronic pulmonary disease, obesity, and especially physical
deconditioning, which is a common cause of effort dyspnea
and fatigue.
A widely quoted study of patients with chronic severe AR
specifically defines symptoms requiring AVR as “overt
evidence of LV failure (paroxysmal nocturnal dyspnea,
orthopnea, or dyspnea at rest), or dyspnea severe enough to
interfere greatly with quality of life” (7). Tarasoutchi et al.
(2) were not as specific with their definition of symptoms.
Thus, they indicate that they operated on some patients
with FC II symptoms, but the discussion suggests that at
least some FC II patients were considered to be asymptom-
atic. In patients with a normal EF, the ACC/AHA guide-
lines suggest AVR in patients with a normal EF and FC III
to IV symptoms, and in patients with a new onset of “mild”
dyspnea if there is evidence of increasing LV size and/or
decreasing EF (both are class I indications). The develop-
ment of “mild” symptoms in a patient with a normal EF and
stable LV size and function may also be an indication for
AVR (a class IIa indication). The problem remains, how-
ever, that early symptoms are often difficult to assess.
Observations made during exercise may contribute to the
evaluation. Ultimately, since symptoms are of signal impor-
tance in the management of patients with chronic AR, it
behooves the physician to be certain of the cardiac origin of
symptoms before recommending AVR.
Age. In virtually all forms of heart disease, age is a strong
correlate of clinical outcome. As Tarasoutchi et al. (2) have
noted, this is no less true of the course of chronic AR. In
their study, the patients that eventually developed symptoms
were an average of seven years older than their asymptom-
atic counterparts. Although the “time of diagnosis” was
similar in the two groups it would seem that differences in
the duration of the LV volume overload could be a deter-
minant of whether or not symptoms develop. Thus, the
patient’s age may well be an extenuating factor that should
be considered when applying the ACC/AHA guidelines or
the “symptom-based strategy.”
Anthropometric normalization. Anthropometric normal-
ization of LV volume or internal diameter should be a
consideration in any study of LV size and function. Unfor-
tunately, Tarasoutchi et al. (2) did not normalize LV
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dimension for body size. Although this would not neces-
sarily have affected their conclusions about symptoms and
clinical outcomes, other important correlations might have
been obscured. In a study contrasting outcomes of men
versus women after surgical correction of chronic AR,
Klodas et al. (9) concluded that the unadjusted LV diameter
criteria established in men are almost never reached in
women. This important observation would seem to support
the concept of normalization for body size, but these
authors found that “LV dimensions corrected for body
surface area (BSA) were not predictive of late survival.” By
contrast, Dujardin et al. (10) found that ESD normalized
for BSA, was a “predictor of outcome.” This result is
consonant with older studies (11), but it might now be
reasonable to question the notion that BSA is appropriate
for this purpose. Normalization for BSA tends to mask the
diagnosis of LV enlargement, especially in patients who are
overweight (12). The use of height and a consideration of
gender are likely to be more appropriate than BSA alone
(13).
Pharmacologic issues. It has long been recognized that
vasoactive drugs have the potential to affect LV size and
function in regurgitant lesion of the mitral and aortic valves
(14). The hydraulic determinants of the regurgitant volume
are well recognized and best understood in the context of
the orifice equation. This equation, based on the Torricelli
principle, states that flow through as orifice varies by the
square root of the pressure gradient across that orifice. Thus,
the major determinants of aortic regurgitant volume are the
regurgitant orifice area, the duration of diastole, and the
diastolic pressure gradient across the valve. In selected
patients, vasoactive and other pharmacologic interventions
can affect all three of these determinants and should be
considered in any study of chronic AR.
Almost one-third of the patients reported by Tarasoutchi et
al. (2) received digitalis or diuretics. Presumably these were
symptomatic patients, but the authors specifically state that
none of the asymptomatic patients were treated with vasodi-
lator drugs. Certainly, no one would argue the use of vasoactive
drugs in symptomatic patients, especially those with depressed
systolic function (14), but the benefits of such treatment in
asymptomatic patients with normal LV function is less well
established. One study indicated that the use of nifedipine
benefited patients in this category (15). Based on measure-
ments of LV size and function, however, the patients that were
treated with nifedipine followed a course that was similar to
untreated, low-risk patients as published by others (6,7,16).
Those treated with digitalis followed a less favorable course and
subsequently a deleterious effect of digitalis was suggested (17).
Bonow et al. (7) also reported the development of symptoms in
two patients that had been treated with digitalis. We do not
use digitalis in asymptomatic, low-risk patients and we gener-
ally reserve the use of vasoactive drugs to patients who are not
in low-risk groups.
Inhibition of the renin-angiotensin system has been shown
to have a salutary cardiac effect in asymptomatic patients with
AR (18). Favorable changes in LV volume and mass are widely
thought to be a consequence of a decrease in regurgitant
volume, but angiotensin-converting enzyme inhibitors also
produce a decrease in LV volume in experimental AR without
a change in regurgitant volume or regurgitant fraction (19).
This can be explained by a systolic unloading effect that results
in an increased LV emptying, with little or no change in the
diastolic pressure gradient across the aortic valve (vide supra).
Therefore, if vasoactive drugs are used in patients with calcific
aortic valve disease and a fixed orifice area, the primary target
should be systolic hypertension and the goal should be after-
load reduction. In patients with aortic root disease, a decrease
in aortic distending pressure may be of further benefit by
directly affecting the regurgitant orifice area.
Conclusions/Comment. The data reported by Tarasout-
chi et al. (2) add to our understanding of the natural history
of chronic AR and provide additional insight into our
deliberations about the timing of AVR. Their experience
confirms a relatively benign natural history of severe AR in
asymptomatic patients with normal LV function, despite
substantial LV enlargement. In such patients, a favorable
outcome can be expected if AVR is postponed until after the
development of symptoms. However, their experience with
patients who have a low EF was very limited, therefore,
their symptom-based strategy should not be extrapolated to
patients with a low EF. Indeed, patients with a decreased
EF are candidates for AVR whether they are symptomatic
or not (a class I indication).
There are clearly circumstances wherein the principle of
primum non nocere may supervene when, for example, as
noted by Tarsoutchi et al. (2), a high rate of prosthetic valve
related complications is anticipated after AVR. In this
situation, temporization and vasodilator treatment, particu-
larly in younger patients, may be justifiable.
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